Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration

Retina

Volumn 34, Issue 7, 2014, Pages 1308-1315

  Young, Mei ^a   Chui, Lica ^a   Fallah, Nader ^b   Or, Chris ^a   Merkur, Andrew B ^a   Kirker, Andrew W ^a   Albiani, David A ^a   Forooghian, Farzin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b RICK HANSEN INSTITUTE   (Canada)

Author keywords

age related macular degeneration; atrophy; bevacizumab; choroid; optical coherence tomography; progression; ranibizumab; retinal pigment epithelium; retrospective; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; CHOROID GYRATE ATROPHY; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; INJECTION; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PIGMENT EPITHELIUM ATROPHY; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; ANTAGONISTS AND INHIBITORS; ATROPHY; CHOROID; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; PATHOLOGY; PIGMENT EPITHELIUM; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ATROPHY; CHOROID; DISEASE PROGRESSION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; POSTOPERATIVE COMPLICATIONS; RETINAL PIGMENT EPITHELIUM; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84903306827     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000081     Document Type: Article

References (22)

1. Friedman DS, O'Colmain BJ, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572. doi:10.1001/archopht.122.4.564. (Pubitemid 38456293)
2. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-1398. doi:10.1016/j.ophtha.2012.03.053.
3. Lois N, McBain V, Abdelkader E, et al. Retinal pigment epithelial atrophy in patients with exudative age-related macular degeneration undergoing anti-vascular endothelial growth factor therapy. Retina 2013;33:13-22. doi: 10.1097/IAE.0b013e3182657fff.
4. Saint-Geniez M, Kurihara T, Sekiyama E, et al. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A 2009;106:18751-18756. doi:10.1073/pnas.0905010106.
5. Branchini L, Regatieri C, Adhi M, et al. Effect of intravitreous anti-vascular endothelial growth factor therapy on choroidal thickness in neovascular age-related macular degeneration using spectral-domain optical coherence tomography. JAMA Ophthalmol 2013;131:1-2. doi:10.1001/jamaophthalmol. 2013.692.
6. Huang D, Swanson E, Lin C, et al. Optical coherence tomography. Science 1991;254:1178-1181. doi:10.1126/science. 1957169. (Pubitemid 21917444)
7. Drexler W, Sattmann H, Hermann B, et al. Enhanced visualization of macular pathology with the use of ultrahigh-resolution optical coherence tomography. Arch Ophthalmol 2003;121:695-706. doi:10.1001/archopht.121. 5.695. (Pubitemid 36554473)
8. Chiu SJ, Izatt JA, O'Connell RV, et al. Validated automatic segmentation of AMD pathology including drusen and geographic atrophy in SD-OCT images. Invest Ophthalmol Vis Sci 2012;53:53-61. doi:10.1167/iovs.11-7640.
9. Maruko I, Iida T, Sugano Y, et al. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010;117:1792-1799. doi:10.1016/j.ophtha.2010. 01.023.
10. Delori F, Dorey C, Staurenghi G, et al. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995;36: 718-729.
11. Lujan BJ, Wang F, Gregori G, et al. Spectral domain optical coherence tomographic imaging of geographic atrophy. Ophthalmic Surg Lasers Imaging 2009;40:96-101. doi:10.3928/ 15428877-20101031-01.
12. Engelbert M, Zweifel SA, Freund KB. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina. 2009;29(10):1424-31. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19898180. Accessed June 2, 2013.
13. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011;31:26-30. doi:10.1097/IAE.0- b013e3181de5609.
14. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117:2134-2140. doi:10.1016/j.ophtha. 2010.02.032.
15. Joachim N, Mitchell P, Kifley A, Rochtchina E, Hong T, Wang JJ. Incidence and progression of geographic atrophy: observations from a population-based cohort. Ophthalmology 2013;120: 2042-2050.
16. Klein R, Meuer SM, Knudtson MD, Klein BEK. The epidemiology of progression of pure geographic atrophy: the Beaver Dam Eye Study. Am J Ophthalmol 2008;146:692-699. doi: 10.1016/j.ajo.2008.05.050.
17. Sunness JS. The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration. Mol Vis 1999;5. Available at: http://www.researchgate.net/ publication/12737855-The-natural-history-of- geographic- atrophy-the-advanced-atrophic-form-of-age-related-macular- degeneration. Accessed June 6, 2013.
18. Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol 2009;147:811-815. doi:10.1016/j. ajo.2008.12.008.
19. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON: A Multicenter Cohort Study (SEVEN-UP). Ophthalmology 2013;120: 2292-2299.
20. Kurihara T, Westenskow PD, Bravo S, et al. Targeted deletion of VEGFa in adult mice induces vision loss. J Clin Invest 2012;122:4213-4217. doi:10.1172/JCI65157.
21. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results. Ophthalmology 2012;119: 1388-1398.
22. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012;32:434-457. doi:10.1097/IAE.0B013E31822C290F.